...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Cytokine >Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega
【24h】

Oral and subcutaneous therapy of canine atopic dermatitis with recombinant feline interferon omega

机译：重组猫干扰素ω口服和皮下治疗犬特应性皮炎

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Canine atopic dermatitis (CAD) is a common allergic skin disease that has been treated with ubcutaneously administered interferons (IFN). Recombinant feline IFN-ω (rFeIFN-ω) was reported to be efficacious for CAD. Whether dogs develop neutralizing antibodies against rFeIFN-ω during long-term treatment and whether orally administered IFNs are efficacious in CAD is unknown. The aim of this study was to evaluate the potential development of antibodies against rFeIFN-ω in atopic dogs and to compare subcutaneous and oral IFN therapy. Twenty-six atopic dogs were randomly assigned to two groups. The first group (n= 15) received eight subcutaneous injections of rFeIFN-ω (Virbagen? omega, Virbac, Carros, France) over four months, the second group (n= 11) received rFeIFN-ω daily orally. Concurrent medication was permitted, except systemically acting glucocorticoids and cyclosporin, which had to be withdrawn at least two weeks prior to the study. Serum samples for antibody detection were collected before and after the study. On days 0, 60 and 120 skin lesions and pruritus were evaluated using a validated lesion score (Canine Atopic Dermatitis Extent and Severity Index = CADESI) and a validated pruritus score. Concurrent medications were recorded. For every visit a total score, consisting of CADESI, pruritus score and medication score was created. For antibody detection an indirect ELISA, using Virbagen? omega as antigen, was performed.Comparison of pruritus scores, CADESI and total scores between days 0 and 120 showed improvement in both groups, however, significant improvement could only be detected in the oral group with CADESI and total scores (61%, P= 0.04 and 36%, P= 0.02 respectively). Serum antibodies against rFeIFN-ω could not be detected in any of the dogs. In this study antibody production could not be demonstrated. It suggests better efficacy with oral IFN administration, which should be further verified in larger, randomized, controlled studies.
机译：犬特应性皮炎（CAD）是一种常见的过敏性皮肤病，已通过皮下注射干扰素（IFN）治疗。据报道重组猫干扰素-ω（rFeIFN-ω）对CAD有效。犬在长期治疗期间是否会产生针对rFeIFN-ω的中和抗体，以及口服给予的IFN在CAD中是否有效。这项研究的目的是评估特应性犬中针对rFeIFN-ω的抗体的潜在发展，并比较皮下和口服IFN治疗。将26只特应性犬随机分为两组。第一组（n = 15）在四个月内接受了八次皮下注射rFeIFN-ω（Virbagen？omega，Virbac，Carros，法国），第二组（n = 11）每天口服rFeIFN-ω。允许并发药物，但全身作用的糖皮质激素和环孢菌素除外，必须在研究前至少两周撤药。在研究之前和之后收集用于抗体检测的血清样品。在第0、60和120天，使用经过验证的病变评分（犬异位性皮炎的程度和严重程度指数= CADESI）和经过验证的瘙痒评分对皮肤病变和瘙痒进行评估。记录并用药物。对于每次访问，都会创建一个总评分，包括CADESI，瘙痒评分和药物评分。对于抗体检测，使用Virbagen？间接ELISA。在第0天和第120天之间比较瘙痒评分，CADESI和总评分在两组中均有改善，但是只有在使用CADESI和总评分的口服组中才能发现显着改善（61％，P = 0.04和36％，P = 0.02）。在任何一只狗中都没有检测到针对rFeIFN-ω的血清抗体。在这项研究中，无法证明抗体的产生。这表明口服干扰素给药具有更好的疗效，应在较大的随机对照研究中进一步验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号